Innova Captab Ltd (INNOVACAP) — FY26 Annual Report | 4 September 2026 (2 announcements)

Innova Captab Limited convened its 22nd AGM on 30 September 2026 via video conference to adopt the Integrated Annual Report for FY 2025-26. The filing highlights FY2026 revenue of ₹1,630.02 Crore (31.1% YoY growth), driven by 23.8% CDMO growth and 51.4% branded generics expansion, alongside 12.5% PAT growth to ₹143.18 Crore. Management emphasized strategic focus on scaling CDMO partnerships, R&D investment of ₹7 Crore, and leveraging India's USD 130 billion pharma market, projecting sustained growth through capacity utilization and Vision 2027 targets.

Innova Captab Limited reported FY 2026 revenue of ₹1,630.02 Crore, up 31.1% YoY, with EBITDA at [amount context mismatch] Crore (26.3% growth) and PAT at ₹143.18 Crore (12.5% growth). CDMO revenue reached ₹1,133.35 Crore (+23.8%), while branded generics surged 51.4% to ₹496.67 Crore. The company plans capacity expansion in Kathua, targeting USD 130 billion pharma and USD 71 billion CDMO markets by 2030-35. Strategic focus remains on scaling CDMO, improving utilization, and disciplined capital allocation amid strong macro trends.